Delivering CRISPR to the HIV-1 Reservoirs

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 May 30

PMID 38812680

Authors

Theodore E Gurrola

Samuel N Effah

Ilker K Sariyer

Will Dampier

Michael R Nonnemacher

Brian Wigdahl

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection is well known as one of the most complex and difficult viral infections to cure. The difficulty in developing curative strategies arises in large part from the development of latent viral reservoirs (LVRs) within anatomical and cellular compartments of a host. The clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9 (CRISPR/Cas9) system shows remarkable potential for the inactivation and/or elimination of integrated proviral DNA within host cells, however, delivery of the CRISPR/Cas9 system to infected cells is still a challenge. In this review, the main factors impacting delivery, the challenges for delivery to each of the LVRs, and the current successes for delivery to each reservoir will be discussed.

Citing Articles

Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication.

Borrajo A Life (Basel). 2025; 15(2).

PMID: 40003685 PMC: 11856976. DOI: 10.3390/life15020276.

References

Atkins A, Allen A, Dampier W, Haddad E, Nonnemacher M, Wigdahl B . HIV-1 cure strategies: why CRISPR?. Expert Opin Biol Ther. 2020; 21(6):781-793. PMC: 9777058. DOI: 10.1080/14712598.2021.1865302. View

Lokugamage M, Sago C, Gan Z, Krupczak B, Dahlman J . Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands. Adv Mater. 2019; 31(41):e1902251. PMC: 6819129. DOI: 10.1002/adma.201902251. View

Cao S, Xu S, Wang H, Ling Y, Dong J, Xia R . Nanoparticles: Oral Delivery for Protein and Peptide Drugs. AAPS PharmSciTech. 2019; 20(5):190. PMC: 6527526. DOI: 10.1208/s12249-019-1325-z. View

Chung C, Allen A, Atkins A, Sullivan N, Homan G, Costello R . Safe CRISPR-Cas9 Inhibition of HIV-1 with High Specificity and Broad-Spectrum Activity by Targeting LTR NF-κB Binding Sites. Mol Ther Nucleic Acids. 2020; 21:965-982. PMC: 7452136. DOI: 10.1016/j.omtn.2020.07.016. View

Rodgers R, Irving-Rodgers H, Russell D . Extracellular matrix of the developing ovarian follicle. Reproduction. 2003; 126(4):415-24. DOI: 10.1530/rep.0.1260415. View

van Marle G, Church D, Nunweiler K, Cannon K, Wainberg M, Gill M . Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology. 2010; 7:74. PMC: 2949729. DOI: 10.1186/1742-4690-7-74. View

Wang C, Sun G, Wang Y, Kong N, Chi Y, Yang L . Bacterial magnetic particles improve testes-mediated transgene efficiency in mice. Drug Deliv. 2017; 24(1):651-659. PMC: 8241085. DOI: 10.1080/10717544.2017.1293195. View

Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T . Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Release. 2000; 69(1):139-48. DOI: 10.1016/s0168-3659(00)00293-5. View

Romberg B, Hennink W, Storm G . Sheddable coatings for long-circulating nanoparticles. Pharm Res. 2007; 25(1):55-71. PMC: 2190344. DOI: 10.1007/s11095-007-9348-7. View

10.

Choi J, Dang Y, Abraham S, Ma H, Zhang J, Guo H . Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016; 23(7):627-33. DOI: 10.1038/gt.2016.27. View

11.

Dampier W, Sullivan N, Chung C, Mell J, Nonnemacher M, Wigdahl B . Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci Rep. 2017; 7(1):14413. PMC: 5663707. DOI: 10.1038/s41598-017-12612-z. View

12.

Cooley M, Sarode A, Hoore M, Fedosov D, Mitragotri S, Sen Gupta A . Influence of particle size and shape on their margination and wall-adhesion: implications in drug delivery vehicle design across nano-to-micro scale. Nanoscale. 2018; 10(32):15350-15364. PMC: 6247903. DOI: 10.1039/c8nr04042g. View

13.

van Ewijk W, Brekelmans P, Jacobs R, Wisse E . Lymphoid microenvironments in the thymus and lymph node. Scanning Microsc. 1988; 2(4):2129-40. View

14.

Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y . Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Theranostics. 2017; 7(3):523-537. PMC: 5327630. DOI: 10.7150/thno.17259. View

15.

Spalding H, Heath T . Fine structure of lymph pathways in nodes from the superficial inguinal lymph centre in the pig. J Anat. 1989; 166:43-54. PMC: 1256738. View

16.

Aird W . Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007; 100(2):158-73. DOI: 10.1161/01.RES.0000255691.76142.4a. View

17.

Ravi P, Vats R, Balija J, Adapa S, Aditya N . Modified pullulan nanoparticles for oral delivery of lopinavir: formulation and pharmacokinetic evaluation. Carbohydr Polym. 2014; 110:320-8. DOI: 10.1016/j.carbpol.2014.03.099. View

18.

Agosto L, Gagne M, Henderson A . Impact of Chromatin on HIV Replication. Genes (Basel). 2015; 6(4):957-76. PMC: 4690024. DOI: 10.3390/genes6040957. View

19.

Kraft J, Treuting P, Ho R . Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities. J Drug Target. 2018; 26(5-6):494-504. PMC: 6205717. DOI: 10.1080/1061186X.2018.1433681. View

20.

Schluep T, Hwang J, Hildebrandt I, Czernin J, Choi C, Alabi C . Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A. 2009; 106(27):11394-9. PMC: 2703672. DOI: 10.1073/pnas.0905487106. View